Tidal Investments LLC Has $1.73 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Tidal Investments LLC raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 52.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 15,043 shares of the company’s stock after buying an additional 5,197 shares during the period. Tidal Investments LLC’s holdings in Neurocrine Biosciences were worth $1,733,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Plato Investment Management Ltd increased its stake in shares of Neurocrine Biosciences by 2,481.9% during the 3rd quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock worth $1,263,000 after purchasing an additional 10,548 shares during the last quarter. Swiss National Bank increased its stake in shares of Neurocrine Biosciences by 1.4% during the 3rd quarter. Swiss National Bank now owns 298,700 shares of the company’s stock worth $34,416,000 after purchasing an additional 4,100 shares during the last quarter. KBC Group NV increased its stake in shares of Neurocrine Biosciences by 78.3% during the 3rd quarter. KBC Group NV now owns 18,972 shares of the company’s stock worth $2,186,000 after purchasing an additional 8,332 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Neurocrine Biosciences by 64.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,421 shares of the company’s stock worth $2,238,000 after purchasing an additional 7,597 shares during the last quarter. Finally, Victory Capital Management Inc. increased its stake in shares of Neurocrine Biosciences by 48.5% during the 3rd quarter. Victory Capital Management Inc. now owns 204,205 shares of the company’s stock worth $23,529,000 after purchasing an additional 66,662 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Price Performance

NBIX stock opened at $136.69 on Wednesday. The company has a 50 day simple moving average of $122.66 and a 200 day simple moving average of $130.57. The stock has a market cap of $13.84 billion, a price-to-earnings ratio of 36.65 and a beta of 0.34. Neurocrine Biosciences, Inc. has a 1 year low of $110.95 and a 1 year high of $157.98.

Insider Buying and Selling

In related news, insider Jude Onyia sold 2,331 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the transaction, the insider now directly owns 15,449 shares in the company, valued at $1,951,054.21. This represents a 13.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a report on Monday, September 16th. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday. Raymond James reaffirmed an “outperform” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Piper Sandler raised shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $131.00 to $159.00 in a report on Thursday, August 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $190.00 target price on shares of Neurocrine Biosciences in a report on Monday. Five research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $165.00.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.